argininosuccinate synthase 1Genealiases: ASS · CTLN1
Q-omics provides the consensus-scored ASS1 profile across patient tissues and cancer cell-line models. ASS1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ASS1 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, ASS1 RNA expression shows 15,675 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRP, and TGCT as cancer lineages where ASS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ASS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ASS1 survival associations across molecular data types. ASS1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ASS1 RNA expression–survival associations across cancer types. High ASS1 expression shows unfavorable associations in UVM, UCEC, BRCA and HNSC, but favorable associations in STAD and BLCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ASS1 RNA expression.
This table summarizes ASS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ASS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ASS1 shows lower tumor expression in KIRP, KICH, KIRC, LIHC and BRCA and higher tumor expression in STAD. The KIRP box plot shows higher ASS1 RNA expression in normal versus tumor tissue (log2 FC = −3.730, t-test p < 0.001).
This table shows molecular features associated with ASS1 in patient tissues and cancer cell lines. In patient samples, ASS1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, ASS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and SOFT_TISSUE.
